Except it might make interpretation easier. With Covid ARDS they have a common cause and aetiology.
So it might make analysis of biomarkers and correlation with clinical outcomes easier.
What is interesting is that Novartis haven't decided to ratify it despite all the glowing post hoc announcements from MSB after dredging the trial data. If it was as clear cut and impressive as SI tries to make out, they wouldn't be hesitating, it would have already been announced, even if there were some aspects not quite complete.
And the idea that a cash and announcement desperate MSB is somehow waiting for Novartis to fulfill some unknown requirements before they will accept the deal simply beggars belief.
New Covid 19 treatment, page-139
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.045(3.33%) |
Mkt cap ! $1.592B | |||
| Open | High | Low | Value | Volume |
| $1.35 | $1.42 | $1.33 | $3.802M | 2.753M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 23940 | $1.39 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 22571 | 2 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |